CN115348972A - 靶向flt3的抗体及其用途 - Google Patents

靶向flt3的抗体及其用途 Download PDF

Info

Publication number
CN115348972A
CN115348972A CN202080072320.1A CN202080072320A CN115348972A CN 115348972 A CN115348972 A CN 115348972A CN 202080072320 A CN202080072320 A CN 202080072320A CN 115348972 A CN115348972 A CN 115348972A
Authority
CN
China
Prior art keywords
ser
amino acid
seq
gly
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080072320.1A
Other languages
English (en)
Chinese (zh)
Inventor
H·巴鲁阿
G·P·常
A·F·张
A·格林伯格
Z·S·宗
T·J·麦奎德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dragonfly Therapy Co ltd
Original Assignee
Dragonfly Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapy Co ltd filed Critical Dragonfly Therapy Co ltd
Publication of CN115348972A publication Critical patent/CN115348972A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080072320.1A 2019-10-15 2020-10-14 靶向flt3的抗体及其用途 Pending CN115348972A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962915120P 2019-10-15 2019-10-15
US62/915,120 2019-10-15
PCT/US2020/055480 WO2021076554A1 (en) 2019-10-15 2020-10-14 Antibodies targeting flt3 and use thereof

Publications (1)

Publication Number Publication Date
CN115348972A true CN115348972A (zh) 2022-11-15

Family

ID=75538063

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080072320.1A Pending CN115348972A (zh) 2019-10-15 2020-10-14 靶向flt3的抗体及其用途

Country Status (16)

Country Link
US (1) US20240228628A9 (https=)
EP (1) EP4045537A4 (https=)
JP (1) JP2022551757A (https=)
KR (1) KR20220082882A (https=)
CN (1) CN115348972A (https=)
AR (1) AR120222A1 (https=)
AU (1) AU2020366000A1 (https=)
BR (1) BR112022006817A2 (https=)
CA (1) CA3153801A1 (https=)
CL (1) CL2022000927A1 (https=)
CO (1) CO2022004743A2 (https=)
IL (1) IL292259A (https=)
MX (1) MX2022004291A (https=)
PE (1) PE20221256A1 (https=)
TW (1) TWI867066B (https=)
WO (1) WO2021076554A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EP4291233A4 (en) * 2021-02-10 2025-05-21 Wugen, Inc. POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
WO2023023491A1 (en) * 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
WO2023105087A1 (en) * 2021-12-10 2023-06-15 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726522A1 (en) * 2008-05-30 2009-12-23 Imclone Llc Anti-flt3 antibodies
CN107614010A (zh) * 2015-03-09 2018-01-19 艾更斯司股份有限公司 结合至flt3蛋白的抗体药物偶联物(adc)
WO2019023097A1 (en) * 2017-07-26 2019-01-31 Smet Pharmaceutical Inc ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE
US20190270817A1 (en) * 2018-01-12 2019-09-05 Amgen Inc. Anti-PD-1 Antibodies and Methods of Treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
HK1255234A1 (zh) * 2015-07-16 2019-08-09 塞勒兰特治疗公司 经半胱氨酸取代的免疫球蛋白
CN118772278A (zh) * 2017-06-02 2024-10-15 辉瑞公司 Flt3的特异性抗体及其用途
JP7317718B2 (ja) * 2017-06-02 2023-07-31 ファイザー・インク Ｆｌｔ３を標的にするキメラ抗原受容体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726522A1 (en) * 2008-05-30 2009-12-23 Imclone Llc Anti-flt3 antibodies
US20110008355A1 (en) * 2008-05-30 2011-01-13 Imclone Llc Anti-flt3 antibodies
CN107614010A (zh) * 2015-03-09 2018-01-19 艾更斯司股份有限公司 结合至flt3蛋白的抗体药物偶联物(adc)
WO2019023097A1 (en) * 2017-07-26 2019-01-31 Smet Pharmaceutical Inc ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE
US20190270817A1 (en) * 2018-01-12 2019-09-05 Amgen Inc. Anti-PD-1 Antibodies and Methods of Treatment

Also Published As

Publication number Publication date
EP4045537A1 (en) 2022-08-24
WO2021076554A1 (en) 2021-04-22
TW202124449A (zh) 2021-07-01
CA3153801A1 (en) 2021-04-22
BR112022006817A2 (pt) 2022-07-05
TWI867066B (zh) 2024-12-21
AU2020366000A1 (en) 2022-05-12
CO2022004743A2 (es) 2022-07-08
MX2022004291A (es) 2022-05-10
PE20221256A1 (es) 2022-08-16
EP4045537A4 (en) 2024-07-17
US20240132598A1 (en) 2024-04-25
AR120222A1 (es) 2022-02-02
CL2022000927A1 (es) 2022-10-28
KR20220082882A (ko) 2022-06-17
IL292259A (en) 2022-06-01
US20240228628A9 (en) 2024-07-11
WO2021076554A8 (en) 2022-04-21
JP2022551757A (ja) 2022-12-13

Similar Documents

Publication Publication Date Title
JP7353576B2 (ja) Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
JP7539840B2 (ja) Ｃｄ３３を標的とする抗体可変ドメイン及びその使用
TWI867066B (zh) 靶向flt3之抗體及其用途
US20220025037A1 (en) Antibody variable domains targeting dll3, and use thereof
US20230220084A1 (en) Antibodies Targeting CLEC12A and Use Thereof
US20240228645A1 (en) Antibodies targeting baff-r and use thereof
JP2023536627A (ja) Ｅｇｆｒを標的とする抗体およびその使用
EA049630B1 (ru) Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination